Brainstorm Cell Therapeutics (BCLI) Misses Q3 EPS by 35c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.53), $0.35 worse than the analyst estimate of ($0.18).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
• The LGL Group (LGL) Misses Q2 EPS by 8c
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)